The estimated Net Worth of Thomas Sandgaard Holdings L... is at least $141 Million dollars as of 14 July 2020. Thomas L owns over 1,250,000 units of Zynex Inc stock worth over $100,948,720 and over the last 6 years Thomas sold ZYXI stock worth over $40,018,294.
Thomas has made over 21 trades of the Zynex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Thomas sold 1,250,000 units of ZYXI stock worth $27,500,000 on 14 July 2020.
The largest trade Thomas's ever made was selling 1,250,000 units of Zynex Inc stock on 14 July 2020 worth over $27,500,000. On average, Thomas trades about 114,473 units every 22 days since 2019. As of 14 July 2020 Thomas still owns at least 12,682,000 units of Zynex Inc stock.
You can see the complete history of Thomas L stock trades at the bottom of the page.
Over the last 6 years, insiders at Zynex Inc have traded over $45,302,249 worth of Zynex Inc stock and bought 14,733 units worth $121,235 . The most active insiders traders include Thomas Sandgaard Holdings L..., Joshua R. Disbrow, and Thomas Sandgaard. On average, Zynex Inc executives and independent directors trade stock every 56 days with the average trade being worth of $657,783. The most recent stock trade was executed by Anna Lucsok on 6 August 2024, trading 24,875 units of ZYXI stock currently worth $199,498.
zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.
Zynex Inc executives and other stock owners filed with the SEC include: